Anavex Life Sciences (AVXL) Cash from Financing Activities (2010 - 2025)

Anavex Life Sciences has disclosed Cash from Financing Activities across 16 years of filings, most recently posting $36.3 million for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $36.3 million, up 5030.37% year-over-year; the trailing twelve-month figure through Dec 2025 was $45.0 million (up 256.85% YoY), and the FY2025 annual result was $9.4 million, down 21.22% from the prior year.
• Cash from Financing Activities came in at $36.3 million for Q4 2025 at Anavex Life Sciences, up from $10.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $89.2 million in Q2 2021 to a low of -$2.1 million in Q2 2025.
• The 5-year median for Cash from Financing Activities is $3.5 million (2021), against an average of $11.8 million.
• Across the five-year window, Cash from Financing Activities jumped 83341.56% in 2023 and plunged 147.1% in 2025, its largest moves.
• Anavex Life Sciences' Cash from Financing Activities stood at $2.5 million in 2021, then slumped by 89.84% to $258000.0 in 2022, then sank by 77.13% to $59000.0 in 2023, then jumped by 1100.0% to $708000.0 in 2024, then soared by 5030.37% to $36.3 million in 2025.
• The last three Cash from Financing Activities figures came in at $36.3 million (Q4 2025), $10.0 million (Q3 2025), and -$2.1 million (Q2 2025), per Business Quant data.